Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 43% of resolved cases
Marianne Dibrino has a lower allowance rate of 42.8% across 635 resolved cases in Art Unit 1641 of Tech Center 1600. The median days to allowance is quite long at 1732, indicating a prolonged prosecution process. However, the interview lift of 42.2% is very high, suggesting that interviews are a critical tool for overcoming the examiner's initial resistance and reaching an allowance.
In Tech Center 1600, practitioners must be prepared for a lengthy prosecution, as evidenced by the 1732-day median. The 42.8% allowance rate suggests that success is not guaranteed, but the 42.2% interview lift offers a powerful way to significantly increase the chances of success compared to the baseline. Given the 635 resolved cases, the data strongly supports the use of interviews as a central part of the prosecution strategy. Applicants should be patient with the 1732-day timeline but proactive in scheduling interviews to leverage the substantial lift in Art Unit 1641.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17018681 | UNIVERSAL DONOR SELECTION METHOD TO IDENTIFY NK-CELL-DONORS | Non-Final OA | The Research Institute at Nationwide Children's Hospital |
| 18157320 | ANTI-C5 ANTIBODIES AND METHODS OF USE | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17272117 | METHODS AND COMPOSITIONS FOR ADOPTIVE T CELL THERAPY INCORPORATING INDUCED NOTCH SIGNALING | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18301048 | TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER | Final Rejection | Baylor College of Medicine |
| 17526812 | MESOTHELIN CARS AND USES THEREOF | Final Rejection | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17426728 | SENOLYTIC CAR-T CELLS TARGETING UPAR, A CELL SURFACE AND SECRETED SENESCENCE BIOMARKER | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18066132 | MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | Final Rejection | CITY OF HOPE |
| 17797419 | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 17687498 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Mammoth Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy